Home/Filings/4/0001654954-25-000690
4//SEC Filing

HALE DAVID F 4

Accession 0001654954-25-000690

CIK 0001853816other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 5:00 PM ET

Size

10.5 KB

Accession

0001654954-25-000690

Insider Transaction Report

Form 4
Period: 2025-01-21
HALE DAVID F
Director
Transactions
  • Award

    Common Stock

    2025-01-23+78,74180,957 total(indirect: By LLC)
  • Award

    Warrant (Right to Buy)

    2025-01-21+78,74178,741 total(indirect: By LLC)
    Exercise: $1.27Common Stock (78,741 underlying)
Holdings
  • Common Stock

    (indirect: By Hale Trading Company L.P.)
    50
  • Common Stock

    (indirect: By Trust)
    148
  • Common Stock

    314
Footnotes (4)
  • [F1]The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
  • [F2]The purchase price per share of Common Stock and accompanying Warrant was $1.27.
  • [F3]The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
  • [F4]Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Issuer

Dermata Therapeutics, Inc.

CIK 0001853816

Entity typeother
IncorporatedCA

Related Parties

1
  • filerCIK 0001024004

Filing Metadata

Form type
4
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 5:00 PM ET
Size
10.5 KB